{
  "drugid": "RxNorm:32624",
  "drugname": "oxcarbazepine",
  "guidelinename": "HLA-A, HLA-B and Carbamazepine and Oxcarbazepine",
  "url": "https://cpicpgx.org/guidelines/guideline-for-carbamazepine-and-hla-b/",
  "guidelinepharmgkbids": [
    "PA166105008",
    "PA166176623"
  ],
  "citations": [
    {
      "pmid": "23695185",
      "title": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for HLA-B Genotype and Carbamazepine Dosing",
      "authors": [
        "Leckband Susan G",
        "Kelsoe John R",
        "Dunnenberger H Mark",
        "George Alfred L",
        "Tran Eric",
        "Berger Reisel",
        "Müller Daniel J",
        "Whirl-Carrillo Michelle",
        "Caudle Kelly E",
        "Pirmohamed Munir"
      ],
      "journal": "Clinical pharmacology and therapeutics",
      "year": 2013
    },
    {
      "pmid": "29392710",
      "title": "Clinical Pharmacogenetics Implementation Consortium Guideline for HLA Genotype and Use of Carbamazepine and Oxcarbazepine: 2017 Update.",
      "authors": [
        "Phillips Elizabeth J",
        "Sukasem Chonlaphat",
        "Whirl-Carrillo Michelle",
        "Müller Daniel J",
        "Dunnenberger Henry M",
        "Chantratita Wasun",
        "Goldspiel Barry",
        "Chen Yuan-Tsong",
        "Carleton Bruce C",
        "George Alfred L",
        "Mushiroda Taisei",
        "Klein Teri",
        "Gammal Roseann S",
        "Pirmohamed Munir"
      ],
      "journal": "Clinical pharmacology and therapeutics",
      "year": 2018
    }
  ],
  "recommendations": [
    {
      "implications": {
        "HLA-B": "Normal risk of oxcarbazepine-induced SJS/TEN"
      },
      "drugrecommendation": "Use oxcarbazepine per standard dosing guidelines.",
      "classification": "Strong",
      "phenotypes": {},
      "activityscore": {},
      "allelestatus": {
        "HLA-B": "HLA-B*15:02 negative"
      },
      "lookupkey": {
        "HLA-B": "*15:02 negative"
      },
      "comments": "n/a",
      "population": "OXC naive",
      "genotypes": null
    },
    {
      "implications": {
        "HLA-B": "Normal risk of oxcarbazepine-induced SJS/TEN"
      },
      "drugrecommendation": "Use oxcarbazepine per standard dosing guidelines.",
      "classification": "Strong",
      "phenotypes": {},
      "activityscore": {
        "HLA-B": "n/a"
      },
      "allelestatus": {
        "HLA-B": "HLA-B*15:02 negative"
      },
      "lookupkey": {
        "HLA-B": "*15:02 negative"
      },
      "comments": "n/a",
      "population": "OXC use >3 mos",
      "genotypes": null
    },
    {
      "implications": {
        "HLA-B": "Greater risk of oxcarbazepine-induced SJS/TEN"
      },
      "drugrecommendation": "If patient is oxcarbazepine-naïve, do not use oxcarbazepine.",
      "classification": "Strong",
      "phenotypes": {},
      "activityscore": {},
      "allelestatus": {
        "HLA-B": "HLA-B*15:02 positive"
      },
      "lookupkey": {
        "HLA-B": "*15:02 positive"
      },
      "comments": "Other aromatic anticonvulsants have weaker evidence linking SJS/TEN with the HLA-B*15:02 allele; however, caution should still be used in choosing an alternative agent. Aromatic anticonvulsants include carbamazepine, oxcarbazepine, eslicarbazepine, lamotrigine, phenytoin, fosphenytoin, and phenobarbital.",
      "population": "OXC naive",
      "genotypes": null
    },
    {
      "implications": {
        "HLA-B": "Greater risk of oxcarbazepine-induced SJS/TEN"
      },
      "drugrecommendation": "The latency period for drug-induced SJS/TEN is short with continuous dosing and adherence to therapy (~4-28 days), and cases usually occur within three months of dosing; therefore, if the patient has previously used oxcarbazepine consistently for longer than three months without incidence of cutaneous adverse reactions, cautiously consider use of oxcarbazepine in the future.",
      "classification": "Optional",
      "phenotypes": {},
      "activityscore": {
        "HLA-B": "n/a"
      },
      "allelestatus": {
        "HLA-B": "HLA-B*15:02 positive"
      },
      "lookupkey": {
        "HLA-B": "*15:02 positive"
      },
      "comments": "Previous tolerance of oxcarbazepine is not indicative of tolerance to other aromatic anticonvulsants. Aromatic anticonvulsants include carbamazepine, oxcarbazepine, eslicarbazepine, lamotrigine, phenytoin, fosphenytoin, and phenobarbital.",
      "population": "OXC use >3 mos",
      "genotypes": null
    }
  ],
  "genes": [
    "HLA-B"
  ],
  "notesonusage": null,
  "cpicVersion": "v1.21.0",
  "source": "CPIC"
}